Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunocore Holdings Plc ADR (NQ: IMCR )

48.18 +1.47 (+3.15%)
Streaming Delayed Price Updated: 1:22 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,321
Open 46.93
Bid (Size) 48.08 (2)
Ask (Size) 48.26 (1)
Prev. Close 46.71
Today's Range 45.92 - 48.40
52wk Range 25.01 - 69.06
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Immunocore to present four posters at AACR Annual Meeting 2023
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore Reports 2022 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via Globe NewsWire

Performance

YTD
-13.06%
-13.06%
1 Month
-12.42%
-12.42%
3 Month
-14.26%
-14.26%
6 Month
+9.50%
+9.50%
1 Year
+64.32%
+64.32%

More News

Read More
Earnings Scheduled For March 1, 2023
Via Benzinga
Preview: Immunocore Holdings's Earnings
Via Benzinga
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore Reveals First Data From HIV Infection Candidate Study
Via Benzinga
Analyst Ratings for Immunocore Hldgs
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
Via Benzinga
7 Analysts Have This to Say About Immunocore Hldgs
Via Benzinga
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
From Immunocore Holdings Limited
Via Globe NewsWire
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers
Via Investor's Business Daily
Is Biotech Immunocore About To Make A 25% Price Move?
Via MarketBeat
Topics ETFs
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via Globe NewsWire
3 Pharma Stocks That Will Mint Millionaires
Via InvestorPlace
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings Limited
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Immunocore is awarded the Prix Galien France award for KIMMTRAK
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
From Immunocore Holdings Limited
Via Globe NewsWire
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
From Immunocore Holdings Limited
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
Via Benzinga
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
From Immunocore Holdings Limited
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.